Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)

Kaplan Fox & Kilsheimer LLP is investigating possible securities law violations involving Corcept Therapeutics, Inc. (NASDAQ: CORT) after significant stock declines following unfavorable news from the FDA regarding its drug relacorilant. The investigation is prompted by a December 31, 2025, announcement wherein the FDA issued a Complete Response Letter (CRL) stating that it could not assess the benefit-risk ratio of relacorilant for treating hypertension associated with hypercortisolism due to insufficient evidence of effectiveness provided by Corcept. This announcement led to a dramatic drop in Corcept's stock price, plummeting over 50% from $70.20 to $34.80 per share.

Further compounding the situation, a subsequent dissemination of a revised CRL on January 30, 2026, indicated the FDA had expressed serious concerns about the adequacy of the clinical development program during prior pre-submission meetings with Corcept. This revelation caused additional stock declines, with intraday trading witnessing a drop of more than $5.60, or over 12%.

Kaplan Fox is actively seeking to connect with investors who may have been adversely affected by these developments, as well as with anyone possessing information relevant to the investigation. The firm specializes in complex litigation and has a robust history in securities litigation that may provide affected investors with recourse.

Interested parties can contact Kaplan Fox directly via email or phone, and more details on the ongoing investigation are available on their website. It's important to note that engaging with Kaplan Fox does not establish an attorney-client relationship. The investigation aims to clarify the potential implications for Corcept and its stakeholders.

Corcept Therapeutics, Inc. (NASDAQ: CORT) is currently facing scrutiny due to an investigation by Kaplan Fox & Kilsheimer LLP regarding potential securities law violations stemming from recent FDA revelations. The negative development concerning the Complete Response Letter (CRL) for the company's new drug, relacorilant, has notably impacted its stock price, which fell over 50% following the initial announcement on December 31, 2025.

This downturn signals immediate concerns for investors. The FDA's reluctance to endorse relacorilant was based primarily on its findings regarding the drug's clinical development program, which could significantly hinder Corcept’s ability to pursue this treatment pathway. Compounding this uncertainty, a subsequent dissemination of information about the FDA's previous warnings regarding the inadequacy of Corcept's application has led to further declines, highlighting the company's tenuous position.

For current investors, we recommend a cautious approach. It may be prudent to re-evaluate exposure to CORT stock in light of these developments, particularly given Mounting legal scrutiny and potential financial ramifications. Investors should consider diversification strategies to mitigate risk. Additionally, it may be beneficial to closely monitor news regarding the investigation as well as Corcept's responses and future strategies to address FDA feedback.

Ultimately, while the potential exists for recovery, based on future clinical data or revised regulatory interactions, it is vital for investors to weigh these prospects against the backdrop of legal uncertainties and operational setbacks. Staying informed via reliable market analyses and updates from regulatory bodies will be key to navigating this volatile situation.